John S. Dunn Gulf Coast Consortium for Chemical Genomics
Putting Gulf Coast investigators ahead of the game in making groundbreaking drug advances and exciting new genome insights.
When the John S. Dunn Gulf Coast Consortium for Chemical Genomics (GCC CG) was organized in 2003, many Gulf Coast institution research laboratories were engaged in screening projects, but they were generally too small to be effective. To reduce the duplication of effort and to expand the screening capabilities, the GCC CG was organized as a research consortium to bring together scientists interested in this area of research with the aim of developing an inter-institutional academic drug discovery program.
The GCC CG’s Screening Lab and Satellite Facilities include the latest automation equipment for assay development and advanced central screening laboratories.
Chemical Genomics Symposium, November 1-2, 2018
About GCC CG
Small Molecules for Research and Medicine: The overall goal of the GCC CG has been to embed within each of the GCC institutions the capability of supporting high throughput and high content screening research projects through an integrated program of specialized equipment and expertise that would be available to individual researchers and research groups. Our strategy has always been to tailor our organization and its operations to match the priorities and the unique capabilities of an academic research center and to build upon the framework of inter-institutional collaboration embodied in the GCC. In addition, the Chemical Genomics Consortium has established a Central High-throughput Screening Laboratory capable of serving as a Core Lab to support large screens for researchers from all the GCC institutions. A special emphasis of the Chemical Genomics Consortium has been on the development of a specialized capability in the application of cell-based imaging technologies to chemical genomics research. As an academic research program, we are interested in exploring how these new technologies can be applied to “non-traditional” targets and to complex biological processes to develop new tools to probe the function of the genome. John S. Dunn, GCC for Chemical Genomics Member Institutions Baylor College of Medicine Rice University Texas Southern University Houston Methodist Research Institute University of Houston The University of Texas Health Science Center at Houston The University of Texas Medical Branch at Galveston The University of Texas M. D. Anderson Cancer Center The Institute of Biosciences and Technology of Texas A&M Health Science Center.
GCC CG Leadership
John S. Dunn GCC Chemical Genomics Co-Directors:
Peter Davies, M.D., Ph.D. Director, Center for Translational Cancer Research Institute of Biosciences & Technology Texas A&M Health Science Center
Michael A. Mancini, Ph.D. Associate Professor Department of Molecular & Cellular Biology Baylor College of Medicine
John S. Dunn GCC Chemical Genomics Executive Committee:
Martin M. Matzuk, M.D., Ph.D. Professor, Department of Molecular and Human Genetics Stuart A. Wallace Chair and Professor, Department of Pathology & Immunology Baylor College of Medicine
Orla Conneely, Ph.D. Professor, Department of Molecular and Cellular Biology Baylor College of Medicine
Scott R. Gilbertson, Ph.D. M. D. Anderson Professor, Department of Chemistry University of Houston
Philip Jones, Ph.D. Head of Drug Discovery, Institute for Applied Cancer Science The University of Texas M.D. Anderson Cancer Center
Stanley Watowich, Ph.D. Associate Professor, Department of Biochemistry & Molecular Biology Scientist, Sealy Center for Structural Biology & Molecular Biophysics University of Texas Medical Branch-Galveston
Kathleen S. Matthews, Ph.D. Stewart Memorial Professor, Biochemistry & Cell Biology Rice University
Stephen T.C. Wong, Ph.D. John S Dunn Distinguished Chair Professor of Radiology, Neurology, & Neurosciences Director, Bioinformatics & Biomedical Engineering Program The Methodist Hospital Research Institute.
Texas Screening Alliance for Cancer Therapeutics